- 期刊
甲狀腺癌之航空醫學考量及缺點免計探討
The Aeromedical Concern and Waiver Consideration of Thyroid Cancer
摘要
甲狀腺癌乃內分泌系統中最常見的腫瘤。除了腫瘤侵犯或轉移，治療的副作用如甲狀腺低下、喉返神經創傷、及副甲狀腺創傷，對於飛行的影響亦不可忽略。本文就本國及美國空軍及海軍教範與民航規範做比較，輔以實際案例討論以探討甲狀腺癌在航空醫學的考量及缺點免計的規範。航空醫學考量主要關注手術及治療的後遺症，包括甲狀腺低下、喉返神經創傷，及副甲狀腺創傷與腫瘤侵犯。癌症本身及部分後遺症在治療良好的狀況下，對飛行 能力是不會有影響的。飛行員在診斷出甲狀腺癌後，會先予以停飛接受治療，包含甲狀腺切除手術、放射碘治療、賀爾蒙替代療法等。但在治療後需繼續監測生化數值、臨床狀況分析及影像學上之變化，才能判斷飛行員是否能重返飛行線。在甲狀腺癌已控制的狀況下，讓飛行員獲得缺點免計並返回飛行線發揮所長。
並列摘要
Thyroid cancer is the most common cancer in the endocrine system. Thus, the purpose of this article is to discuss the aeromedical concerns and waiver of thyroid cancer. We compared our guidelines with those of US air force, US navy, and Federal Aviation Administration(FAA). We also reviewed three cases from the FAA and France medical journal. We concluded that the aeromedical concern of thyroid cancer is mostly about the side effects of its therapy: hypothyroidism, retropharyngeal nerve injury and parathyroid gland injury. Aviators are considered disqualified when diagnosed with thyroid cancer. Waiver may be considered when treatment is completed, there were no metastasis and that the aircrew is under euthyroid state.